UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware 27-5411038 (State or other jurisdict ...

Exhibit 99.1 Personalis Reports Second Quarter 2024 Financial Results Strong Revenue Growth of 35% Year-over-Year Driven by 117% Growth from Biopharma Business Raises 2024 Full Year Revenue Guidance FREMONT, Calif. – August 7, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2024, and provided recent business accomplishments. Recent Business Accomplishments | --- | --- | |--------|------------ ...

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumorinformed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing. "Myriad an ...

Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Chris Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Rich Chen - Chief Medical Officer and Executive Vice President, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Dan Brennan - TD Cowen Thomas Flaten - Lake Street Mike Mattson - Needham Arthur He - H.C. Wainwright Operator Good day and welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware 27-5411038 (State or other jurisdic ...

Exhibit 99.1 Personalis Reports First Quarter 2024 Financial Results Raises full year revenue guidance due to greater pharma testing demand FREMONT, Calif. – May 8, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights. Recent Business Highlights • The analytical validation for the company’s NeXT Personal MRD test was published in Oncotarget on ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Daniel Sammarco - TD Cowen Operator Greetings, and welcome to the Personalis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) Delaware 27-5411038 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6600 Dumbarton Circle Fremont, California 94555 W ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Participating on Tuesday, February 13, 2024 at The Cliff Lodge in Snowbird, UT 44th Annual Cowen Healthcare Conference Presenting on Wednesday, March 6, 2024 at 12:50 p.m. Eastern Time at the Boston Marriott Copley Place in Bost ...